Necitumumab: First Global Approval

O3-9-2A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

(2017) Hiroshi Nokihara et al.   ANNALS OF ONCOLOGY

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

(2015) Nick Thatcher et al.   LANCET ONCOLOGY

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

(2015) Luis Paz-Ares et al.   LANCET ONCOLOGY

EGFR-directed monoclonal antibodies in non-small cell lung cancer

(2013) Robert Pirker   Targeted Oncology

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

(2010) B. Kuenen et al.   CLINICAL CANCER RESEARCH

Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8

(2008) Shiqing Li et al.   STRUCTURE